success fail Jun JUN Dec 06 2009 2011 2013 21 captures 12 Aug 2007 - 28 Jun 2019 About this capture COLLECTED BY Organization: Alexa Crawls Starting in 1996, Alexa Internet has been donating their crawl data to the Internet Archive. Flowing in every day, these data are added to the Wayback Machine after an embargo period. Collection: Alexa Crawls Starting in 1996, Alexa Internet has been donating their crawl data to the Internet Archive. Flowing in every day, these data are added to the Wayback Machine after an embargo period. TIMESTAMPS News LATEST NEWS More from MedscapeReference Browse Reference Tools Education Medscape Education CME/CE Tracker Medscape Today Log InRegister
Paradoxical Reactions to Benzodiazepines: Midazolam
- Abstract and Introduction
- Literature Evaluation: Adults
- Lorazepam and Diazepam
- Alprazolam and Temazepam
- Triazolam and Clonazepam
- Literature Evaluation: Children
- Treatment Options
Reports of paradoxical reactions to midazolam are a recent development in the medical literature. Midazolam, which has sedative effects, is commonly prescribed before short surgical procedures.
While participating in a study to evaluate benzodiazepine potency, 28-year-old healthy, identical twin men experienced similar paradoxical reactions. On three separate occasions, the men received various dosages of midazolam and diazepam. After receiving intravenous midazolam 5 mg, one of the twins became sedated with restlessness and heightened motor responses of his extremities. An additional dose of midazolam 5 mg heightened these responses. On the second occasion, one of the men became unconscious after receiving intravenous midazolam 12 mg. When he awoke, he was extremely restless and agitated. Administration of intravenous diazepam 10 mg resulted in similar but less intensive sedation and motor responses. The second twin displayed the same responses. Neither man had any recollection of the events. The authors stated that the intensity of the behaviors was so strong that if this had been an actual procedure and not an experiment, the procedure would have had to be discontinued. These cases demonstrate that paradoxical reactions to benzodiazepines may be genetically linked.
Another case report describes aggressive behaviors in a patient with anger management difficulties. A 31-year-old man was hospitalized for an endogastric-duodenoscopy to evaluate recent complaints of epigastric pain with fever. Before the procedure, the man received midazolam 5 mg intravenously. Soon thereafter, he became verbally and physically threatening to an extent that necessitated restraint. The behaviors ceased after he received an intramuscular injection of sodium amobarbital 200 mg. The authors did not mention if the procedure was reattempted at a later time.
Paradoxical reactions to midazolam occurred during surgical removal of impacted molars in a 22-year-old woman with a history of anger management problems and alcohol abuse sufficient to require rehabilitation. The patient was enrolled in a multicenter clinical trial to evaluate the safety and efficacy of intravenous sedatives. The study protocol randomly assigned participants to one of five groups to receive various combinations of midazolam, fentanyl, and methohexital. The dosage of midazolam was titrated to slurred speech and ptosis, with a maximum dose not to exceed 25 mg. After receiving midazolam 18 mg over 18 minutes, the woman became belligerent and verbally abusive, with disruptive movement of her extremities. The dental procedure was terminated due to these extreme behaviors, which continued for the next 24 hours. Afterward, the woman had no recollection of the events. Based on this case, the authors suggested that a history of alcohol abuse may predispose patients to paradoxical reactions with benzodiazepines.
Other authors described a case of agitation secondary to midazolam successfully managed with haloperidol. A 50-year-old man with a medical history of hypercholesterolemia was hospitalized for coronary artery bypass grafting (CABG) surgery after presenting with chest pain consistent with myocardial infarction and 90% occlusion of the coronary artery. The patient received intravenous midazolam before placement of the arterial catheter. After a total dose of 6 mg was administered, the man developed worsening anxiety and agitation. The physician chose to treat the paradoxical reaction with haloperidol 10 mg delivered intravenously over 2 minutes. The patient calmed, the CABG procedure was completed, and amnesia was retained. The authors concluded that haloperidol may be a safe and effective agent for treating paradoxical reactions of benzodiazepines.
Several reports indicate that the benzodiazepine antagonist flumazenil may be useful in the treatment of paradoxical reactions to midazolam. Flumazenil should be considered if these types of reactions are suspected.
A 49-year-old healthy woman experienced a paradoxical reaction while under conscious sedation during insertion of breast implants. Midazolam was started before the procedure and administered throughout the procedure, in varying doses as needed, until adequate sedation was attained. Vital signs were monitored and remained within normal limits during the surgery. In general, every time the woman moved during the procedure, additional midazolam was delivered. This pattern was repeated several times, and she received a total dose of midazolam 12 mg intravenously over 70 minutes. Fluma-zenil 0.5 mg was administered intravenously when her movements became very aggressive and required force to control. Her aggressiveness ceased after receiving flumazenil; however, she remained sedated and amnesia was retained.
In another report, a 71-year-old man with a 1-year history of episodes of increased anger, jealousy, and paranoid ideation, experienced paradoxical reactions to midazolam before an endoscopy. One month earlier, the patient had undergone an uneventful endoscopy procedure. On this occasion, after receiving midazolam 4 mg intravenously over 14 minutes, he became sedated and delirious, requiring restraint for increased movement of his extremities. The behaviors were reversed after administration of intravenous flumazenil 0.2 mg. The man did not remember the events. This case illustrates that elderly patients, as well as those with psychiatric disturbances, may be at increased risk for paradoxical reactions to benzodiazepines.
One case report indicated that patients without psychiatric disorders also may experience paradoxical reactions with benzodiazepines. A 27-year-old man received a total dose of midazolam 7 mg intravenously before cystoscopy and laser ablation of a meatal condyloma. The surgery was completed despite his agitated and restless behavior. Vital signs remained within normal limits and the patient denied pain. Postoperatively, he received lorazepam 4 mg intravenously with no change in behavior. The agitation ceased after administration of flumazenil 0.3 mg (total dose), and amnesia was retained.
Flumazenil effectively reversed paradoxical reactions of midazolam in three patients undergoing endoscopy procedures. The first patient, a 62-year old man with a long history of alcohol abuse, experienced movement of the extremities with head shaking after receiving midazolam 5 mg intravenously. The second patient, a 58-year-old woman, also with a history of alcohol abuse, became restless and agitated after receiving midazolam 7.5 mg intravenously. The last patient, a healthy 26-year-old man, had violent movements after receiving midazolam 10 mg intravenously. In all three patients, the paradoxical reactions were reversed by intravenous flumazenil 0.5 mg. Sedation was maintained, the procedures were completed, and no patient had any recollection of the unusual behaviors.
A case series of patients who underwent minor to medium lower body surgical procedures addressed the development of paradoxical reactions to midazolam. All patients were given spinal or epidural anesthesia and incremental injections of midazolam 1.5 mg intravenously to induce sedation. Six of 58 patients experienced paradoxical reactions to midazolam. The authors compared these patients with six matched control subjects who received midazolam uneventfully. The paradoxical reactions were characterized as flailing of the arms, writhing on the examination table, and attempting to speak during the surgical procedures. All six patients were delirious and needed to be physically restrained due to their aggressive behavior. The mean ± SD total dose of midazolam was 7.3 ± 2.8 mg, which was similar in the six matched controls (8.8 ± 3.2 mg). Flumazenil was administered in all six patients, with total doses ranging from 0.3-0.5 mg. The paradoxical reactions ceased after administration of flumazenil, and all patients completed the surgical procedure and were discharged successfully.
The most recent report described two cases of paradoxical reactions in patients given midazolam for dental procedures. An anxious 19-year-old woman requested sedation before molar extraction. After receiving midazolam 5 mg intravenously over 7 minutes, she became uncooperative and began crying, yet denied pain. A 21-year-old woman displayed a similar response after receiving midazolam 7 mg intravenously over 10 minutes. In both cases, the women calmed and ceased crying after receiving flumazenil 0.2-0.4 mg intravenously. Neither patient had any memory of the events.« Previous Page Section 6 of 9 Next: Literature Evaluation: Children »
- Abstract and Introduction
- Literature Evaluation: Adults
- Lorazepam and Diazepam
- Alprazolam and Temazepam
- Triazolam and Clonazepam
- Literature Evaluation: Children
- Treatment Options
- Hall RW, Zisook S. Paradoxical reactions to benzodiazepines. Br J Clin Pharmacol 1981;11:99-104S.
- Weinbroum AA, Szold O, Ogorek D, Flasishon R. The midazolam-induced paradox phenomenon is reversible by flumazenil: epidemiology, patient characteristics and review of the literature. Eur J Anaesthesiol 2001;18:789-97.
- Short TG, Forrest P, Galletly DC. Paradoxical reactions to benzodiazepines: a genetically determined phenomenon? Anaesth Intens Care 1987;15:330-45.
- Fiset L, Milgrom P, Beirne R, Roy-Byrne P. Disinhibition of behaviors with midazolam: report of a case. J Oral Maxillofac Surg 1992;50:645-9.
- Strahan A, Rosenthal J, Kaswan M, Winston A. Three case reports of acute paroxysmal excitement associated with alprazolam treatment. Am J Psychiatry 1985;142:859-61.
- Binder RL. Three case reports of behavioral disinhibition with clonazepam. Gen Hosp Psychiatry 1987;9:151-3.
- Miwa LJ, Lobo BL. Midazolam disinhibition reaction [letter]. Drug Intell Clin Pharm 1988;22:725.
- Goldney RD. Paradoxical reaction to a new minor tranquilizer. Med J Aust 1977;1:139-40.
- Gardos G. Disinhibition of behavior by antianxiety drugs. Psychosomatics 1980;21:1025-6.
- Regestein QR, Reich P. Agitation observed during treatment with newer hypnotic drugs. J Clin Psychiatry 1985;46:280-3.
- Marchevsky S, Isaacs G, Nitzan I. Behavioral disinhibition with clonazepam [letter]. Gen Hosp Psychiatry 1988;10:447.
- Khan LC, Lustik SJ. Treatment of a paradoxical reaction to midazolam with haloperidol. Anesth Analg 1997;85:213-15.
- Rodrigo CR. Flumazenil reverses paradoxical reaction with midazolam. Anesth Prog 1991;38:65-8.
- Honan VJ. Paradoxical reaction to midazolam and control with flumazenil. Gastrointest Endosc 1994;40:86-8.
- Thurston TA, Williams CGA, Foshee S. Reversal of a paradoxical reaction to midazolam with flumazenil. Anesth Analg 1996;83:192.
- Fulton SA, Mullen KD. Completion of upper endoscopic procedures despite paradoxical reaction to midazolam: a role for flumazenil? Am J Gastroenterol 2000;95:809-11.
- Robin C, Trieger N. Paradoxical reactions to benzodiazepines in intravenous sedation: a report of 2 cases and review of the literature. Anesth Prog 2002;49:128-32.
- Roelofse JA, Stegmann DH, Hartshorne J, Joubert JJ. Paradoxical reactions to rectal midazolam as premedication in children. Int J Oral Maxillofac Surg 1990;19:2-6.
- Doyle WL, Perrin L. Emergence delirium in a child given oral midazolam for conscious sedation. Ann Emerg Med 1994;24:1173-5.
- Thakker P, Gallagher TM. Flumazenil reverses paradoxical reaction to midazolam in a child. Anaesth Intens Care 1996;24:505-7.
- Massanari M, Novitsky J, Reinstein LJ. Paradoxical reactions in children associated with midazolam use during endoscopy. Clin Pediatr 1997;36:681-4.
- Saltik IN, Ozen H. Role of flumazenil for paradoxical reaction to midazolam during endoscopic procedures in children. Am J Gastroenterol 2000;95:3011-12.
- Caldwell CB, Gross JB. Physostigmine reversal of midazolam-induced sedation. Anesthesiology 1982;57:125-7.
- Ross W. Premedication for upper gastrointestinal endoscopy. Gastrointest Endosc 1989;35:120-6.
- Garber JG, Ominsky AJ, Orkin FK, Quinn P. Physostigmine-atropine solution fails to reverse diazepam sedation. Anesth Analg 1980;59:58-60.
- Milam SB, Bennett CR. Physostigmine reversal of drug-induced paradoxical excitement. Int J Oral Maxillofac Surg 1987;16:190-3.
- Whitwam JG, Amrein R. Pharmacology of flumazenil. Acta Anaesthesiol Scand 1995;39(suppl 108):3-14.
- Roche Pharmaceuticals. Romazicon (flumazenil) injection package insert. Nutley, NJ; 2000.
- McEvoy GK, ed. AHFS drug information 2003. Bethesda, MD: American Society of Health-System Pharmacists, 2003.
Table 1. Table 1. Summary of Paradoxical Reactions in AdultsAge (yrs),
SexDaily Drug DoseTreatmentOutcomeConcomitant Psychiatric
or Medical Conditions 67, M Midazolam 15 mg i.v. Flumazenil 0.5 mg i.v. Restlessness resolved Coronary artery disease, atrial fibrillation 66, M Midazolam 3 mg i.v. Flumazenil 0.3 mg i.v. Restlessness resolved Obstructive lung disease, alcoholism 65, M Midazolam 18 mg i.v. Flumazenil 0.4 mg i.v. Body rocking resolved None noted 73, M Midazolam 6 mg i.v. Flumazenil 0.4 mg i.v. Restlessness resolved Diabetes mellitus 70, M Midazolam 6 mg i.v. Flumazenil 0.3 mg i.v. Restlessness, vocalizations resolved Diabetes mellitus, coronary artery disease 76, M Midazolam 9 mg i.v. Flumazenil 0.3 mg i.v. Restlessness, vocalizations resolved Diabetes mellitus, atrial fibrillation 28, M
(twins) Midazolam 12 mg i.v. None Restlessness resolved and retained amnesia None noted Diazepam 10 mg p.o. None Restlessness resolved and retained amnesia None noted 22, F Midazolam 18 mg i.v. None Abusive, belligerent behavior ceased within 24 hrs Alcoholism, anger management issues 32, F Alprazolam 1.5 mg p.o. Discontinued Racing thoughts, increased energy resolved in 48-72 hrs Depressive bipolar disease 34, M Alprazolam 3 mg p.o. Discontinued Racing thoughts, paranoid feelings resolved in 72 hrs Anxiety, panic attacks 32, F Alprazolam 1 mg p.o. Discontinued Racing thoughts and insomnia resolved in 48 hours Panic attacks 37, M Clonazepam 12 mg p.o. Discontinued Aggressive behavior ceased Bipolar affective disorder 25, M Clonazepam 4.5 mg p.o. Discontinued Hyperactivity, belligerence ceased Bipolar affective disorder 19, M Clonazepam 4 mg p.o. Discontinued Agitation ceased Borderline personality disorder 31, M Midazolam 5 mg i.v. Sodium amobarbital
200 mg i.m. Combative, verbally threatening behavior ceased Anger management issues 22, F Lorazepam 3 mg p.o. Discontinued Hostile behavior resolved Phobia of elevators and escalators 28, F Diazepam 20 mg p.o. Discontinued Improvement of hostile, physical abuse in 48-72 hrs Depression, anxiety 30, F Temazepam 30 mg p.o. at bedtime Discontinued Anger and enraged behavior ceased Manic-depression 30, M Temazepam 30 mg p.o. at bedtime Discontinued Anger and agitation resolved, no recollection of events Chronic insomnia 37, M Temazepam 30 mg p.o. at bedtime Discontinued Anger resolved Schizophrenia 39, F Temazepam 15-30 mg p.o. at bedtime Discontinued Agitation and restlessness resolved Obsessive-compulsive symptoms 75, F Triazolam 0.5 mg p.o. every other night Discontinued Agitation and nervousness resolved Chronic insomnia 40, M Triazolam 1-1.5 mg p.o. at bedtime Discontinued Anger, panic, visual hallucinations ceased Chronic insomnia 60, F Triazolam 0.5-1 mg p.o. at bedtime Discontinued Anger and argumentative behaviors ceased Chronic insomnia 29, F Triazolam 0.5 mg p.o. at bedtime Discontinued Anxiety and agitation resolved Chronic insomnia 64, F Triazolam 0.5 mg p.o. at bedtime Discontinued Bizarre behaviors ceased Chronic insomnia 56, F Triazolam 0.5 mg p.o. at bedtime Discontinued Agitation ceased over 2 days Chronic insomnia 37, M Clonazepam 8 mg p.o. Discontinued Irritability, hyperactivity ceased Manic episodes, panic attacks 50, M Midazolam 6 mg i.v. Haloperidol 10 mg i.v. Patient calmed, retained amnesia Coronary artery disease 49, F Midazolam 12 mg i.v. Flumazenil 0.5 mg i.v. Aggressive behavior ceased, retained amnesia None noted 71, M Midazolam 4 mg i.v. Flumazenil 0.2 mg i.v. Patient calmed, retained amnesia Anger management issues 27, M Midazolam 7 mg i.v. Flumazenil 0.3 mg i.v. Patient calmed, retained amnesia None noted 62, M Midazolam 5 mg i.v. Flumazenil 0.5 mg i.v. Patient calmed, retained amnesia Alcoholism 58, F Midazolam 7.5 mg i.v. Flumazenil 0.5 mg i.v. Patient calmed, retained amnesia Alcoholism 26, M Midazolam 10 mg i.v. Flumazenil 0.5 mg i.v. Patient calmed, retained amnesia None noted 19, F Midazolam 5 mg i.v. Flumazenil 0.2 mg i.v. Crying ceased, retained amnesia None noted 21, F Midazolam 7 mg i.v. Flumazenil 0.4 mg i.v. Crying ceased, retained amnesia None noted [ ]
Table 2. Table 2. Summary of Paradoxical Reactions in Pediatric PatientsNo. of
(yrs)SexDrug, Maximum DoseTreatmentOutcome 14 2-7 NR Midazolama 0.35 mg/kg (n=4)
Midazolama 0.45 mg/kg (n=10) None Agitation, restlessness resolved 1 26 mos F Midazolam 0.5 mg/kg p.o. Morphine sulfate 0.1 mg/kg i.v. Calmed, ceased crying 1 11 M Midazolam 17.5 mg p.o. Flumazenil 0.15 mg i.v. Confusion, screaming ceased, amnesia retained 36 1-17 19 M
17 F Midazolam 0.1-0.5 mg/kg i.v.
Meperidine 1-2 mg/kg i.v. Flumazenil 0.01 mg/kg i.v. (n=30)
Physostigmine i.v. (dose unknown, n=6) Inconsolable crying, restlessness resolved 25 2.5-18 NR Midazolam 0.1-0.3 mg/kg i.v.
Meperidine 1-2 mg/kg i.v. Flumazenil 0.01 mg/kg i.v. i.v. (n=2) Agitation resolved
NR = not reported.
aRoute of administration was per rectum.
Authors and Disclosures
Carissa E. Mancuso, Pharm.D., Maria G. Tanzi, Pharm.D., and Michael Gabay, Pharm.D., Department of Pharmacy Practice, College of Pharmacy, University of Illinois, Chicago, Illinois
Pharmacotherapy. 2004;24(9) © 2004 Pharmacotherapy Publications
Copyright © 1999, Pharmacotherapy Publications, Inc., All rights reserved.
Topic AlertThank you for subscribing to Topic Alert.
Prostate Cancer is already on your Topic Alert list.
"Prostate Cancer" has been added to your Topic Alert list. You will receive an email when new content is available from Medscape on your selected topics.
If you subscribed to this topic in error or wish to manage your Topic Alert list click here.MOST POPULAR ARTICLES − ACCORDING TO PHYSICIANS Most Emailed Top Rated
- Cell Phone Use Affects Brain Glucose Metabolism
- Vitamin D Supplementation: An Update
- 2010 ACCF/AHA Guideline for Assessment of Cardiovascular Risk in Asymptomatic Adults: Executive Summary
- Cell Phones Possibly Carcinogenic, WHO Says
- The 2010 AHA Guidelines: The 4 Cs of Cardiac Arrest Care
- Be on Alert for 'Super Toxic' Bug in Travelers, CDC Says
- Gaming Devices Cause Children Pain in Fingers, Wrists
- Changes in Oncology Practice Could Save Billions
- Beta-Blockers Tied to Breast Cancer Survival
- Vitamin D Supplementation Boosts COPD Rehabilitation